Effects of neratinib on angiogenesis and the early stage of the embryo using chicken embryo as a model
Angiogenesis is the process of forming new blood capillaries from pre-existing vessels. Even though it is essential during normal development, it plays a major role in cancer progression. Neratinib is a pan-human epidermal growth factor receptor (HER) inhibitor that has recently been approved for the treatment of HER2-positive breast cancer. However, its effects on angiogenesis and embryogenesis remain unknown. This study examined the antiangiogenic effects of neratinib using the chorioallantoic membrane (CAM) of chicken embryos. We also evaluated neratinib's toxicity during the early stages of normal development using the chicken embryos, primary embryonic fibroblasts (EFBs) and human umbilical vein endothelial cells (HUVEC). Our findings revealed that neratinib significantly inhibited the CAM angiogenesis compared to controls by reducing vessel percentage area and the average vessel length. Furthermore, neratinib downregulated vascular endothelial growth factor (VEGF), a key mediator of angiogenesis. At lower concentrations, neratinib was well-tolerated during early stages of normal development. Additionally, EFBs treated with neratinib showed no morphological or viability changes when compared to controls. However, at the highest concentration tested, neratinib treatment reduced HUVEC cell viability. This effect may be associated with the dysregulation of key apoptotic genes, including caspase-3, caspase-8, caspase-9, and the B-cell lymphoma 2 (Bcl2) gene. Our findings indicate a novel potential application of neratinib as an antiangiogenic agent, exhibiting tolerable toxicity in the early stages of embryogenesis.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - year:2023 |
---|---|
Enthalten in: |
Biomolecules & biomedicine - (2023) vom: 27. Dez. |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Kheraldine, Hadeel [VerfasserIn] |
---|
Links: |
---|
Themen: |
---|
Anmerkungen: |
Date Revised 30.12.2023 published: Print-Electronic Citation Status Publisher |
---|
doi: |
10.17305/bb.2023.9869 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM366494309 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM366494309 | ||
003 | DE-627 | ||
005 | 20240108140949.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240108s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.17305/bb.2023.9869 |2 doi | |
028 | 5 | 2 | |a pubmed24n1246.xml |
035 | |a (DE-627)NLM366494309 | ||
035 | |a (NLM)38158791 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Kheraldine, Hadeel |e verfasserin |4 aut | |
245 | 1 | 0 | |a Effects of neratinib on angiogenesis and the early stage of the embryo using chicken embryo as a model |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 30.12.2023 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status Publisher | ||
520 | |a Angiogenesis is the process of forming new blood capillaries from pre-existing vessels. Even though it is essential during normal development, it plays a major role in cancer progression. Neratinib is a pan-human epidermal growth factor receptor (HER) inhibitor that has recently been approved for the treatment of HER2-positive breast cancer. However, its effects on angiogenesis and embryogenesis remain unknown. This study examined the antiangiogenic effects of neratinib using the chorioallantoic membrane (CAM) of chicken embryos. We also evaluated neratinib's toxicity during the early stages of normal development using the chicken embryos, primary embryonic fibroblasts (EFBs) and human umbilical vein endothelial cells (HUVEC). Our findings revealed that neratinib significantly inhibited the CAM angiogenesis compared to controls by reducing vessel percentage area and the average vessel length. Furthermore, neratinib downregulated vascular endothelial growth factor (VEGF), a key mediator of angiogenesis. At lower concentrations, neratinib was well-tolerated during early stages of normal development. Additionally, EFBs treated with neratinib showed no morphological or viability changes when compared to controls. However, at the highest concentration tested, neratinib treatment reduced HUVEC cell viability. This effect may be associated with the dysregulation of key apoptotic genes, including caspase-3, caspase-8, caspase-9, and the B-cell lymphoma 2 (Bcl2) gene. Our findings indicate a novel potential application of neratinib as an antiangiogenic agent, exhibiting tolerable toxicity in the early stages of embryogenesis | ||
650 | 4 | |a Journal Article | |
700 | 1 | |a Hassan, Arij Fouzat |e verfasserin |4 aut | |
700 | 1 | |a Alhussein, Hashim |e verfasserin |4 aut | |
700 | 1 | |a Al-Thawadi, Hamda |e verfasserin |4 aut | |
700 | 1 | |a Vranic, Semir |e verfasserin |4 aut | |
700 | 1 | |a Al Moustafa, Ala-Eddin |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Biomolecules & biomedicine |d 2023 |g (2023) vom: 27. Dez. |w (DE-627)NLM327045957 |x 2831-090X |7 nnns |
773 | 1 | 8 | |g year:2023 |g day:27 |g month:12 |
856 | 4 | 0 | |u http://dx.doi.org/10.17305/bb.2023.9869 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |j 2023 |b 27 |c 12 |